secwatch / observer
8-K filed March 26, 2025, 7:59 PM ET ticker RFL CIK 0001713863
M&A confidence high sentiment positive materiality 0.90

Rafael Holdings, Inc. (RFL): M&A transaction — Rafael Holdings completes merger with Cyclo Therapeutics after shareholder approvals

Rafael Holdings, Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Markus W. Sieger

Director
RFL · Rafael Holdings, Inc.
Effective
2025-03-25
Filed
March 26, 2025, 7:59 PM ET
On March 25, 2025, effective as of the Effective Time, Markus W. Sieger, former Chairman of the Board of Cyclo, was appointed as a member of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Markus W. Sieger was appointed as Director at Rafael Holdings, Inc..

Action
appointed
Role
Director
Exact text from the filing
On March 25, 2025, effective as of the Effective Time, Markus W. Sieger, former Chairman of the Board of Cyclo, was appointed as a member of the Board.
View on SEC.gov
M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Rafael Holdings, Inc. completed an acquisition involving Cyclo Therapeutics, Inc. (closed 2025-03-25).

Action
acquisition
Counterparty
Cyclo Therapeutics, Inc.
Closing
2025-03-25
Exact text from the filing
On March 25, 2025, Rafael Holdings, Inc., a Delaware corporation (“Rafael”), completed the previously announced business combination transaction with Cyclo Therapeutics, Inc., a Nevada corporation (“Cyclo”) contemplated by that certain Agreement and Plan of Merger, dated as of August 21, 2024
View on SEC.gov

82 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Rafael Holdings, Inc. filing history →

Source: SEC EDGAR
accession 0001013762-25-002413
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.